Cannara Biotech Inc.
LOVE.TO
TSX
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -7.61% | 4.88% | |||
| Total Other Revenue | -- | -90.37% | |||
| Total Revenue | -7.71% | 3.74% | |||
| Cost of Revenue | -15.89% | 15.17% | |||
| Gross Profit | 6.08% | -11.13% | |||
| SG&A Expenses | -2.26% | 23.43% | |||
| Depreciation & Amortization | -2.93% | -66.30% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.19% | 14.96% | |||
| Operating Income | 27.62% | -47.87% | |||
| Income Before Tax | 41.45% | -55.84% | |||
| Income Tax Expenses | 18.30% | -19.84% | |||
| Earnings from Continuing Operations | 63.74% | -69.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.74% | -69.18% | |||
| EBIT | 27.62% | -47.87% | |||
| EBITDA | 11.96% | -42.92% | |||
| EPS Basic | 60.76% | -70.08% | |||
| Normalized Basic EPS | 42.86% | -51.00% | |||
| EPS Diluted | 76.39% | -67.12% | |||
| Normalized Diluted EPS | 44.21% | -51.28% | |||
| Average Basic Shares Outstanding | 2.82% | 2.49% | |||
| Average Diluted Shares Outstanding | 2.33% | 3.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||